Expert Interview
A Second Perspective: Examining the potential of STRO-002, Sutro's FolRα-targeting ADC in treating ovarian cancer
Ticker(s): STROInstitution: University College London
- Professor of Medical Oncology and Clinical Director at UCL Cancer Institute and a Consultant Medical Oncologist at UCL Hospitals, London, UK where he has worked for more than 30 years.
- Sees ~130 new cases of ovarian cancer referred to his center each year.
- Specialises in the treatment of gynaecological cancers and has led several national and international trials in ovarian cancer; has published widely in the areas of clinical trials in gynaecological cancers, experimental therapeutics, guidelines, and education in gynaecological malignancies.
Roughly how many patients with ovarian cancer do you currently manage?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for STRO-002?
Added By: c_adminExamining STRO-002 recent dose expansion data update in January. Overall impression of the data, safety and efficacy
Added By: user1ae2bf5fNeutropenia with STRO-002 - 40% Grade 4 in the 5.2mg dose, with 1 grade 5 Death
17% grade 4 in 4.3 mg dose. How manageable is this? Is either dose level viable?
Efficacy when looked at in context of dose reductions due to neutropenia and focusing on 4.3 dose which seems likely to be the go-forward dose.
18.8% in that subgroup - Your view in context of competitive data in similar setting from other agents
Does mirvetuximab soravtansine data in SORAYA trial in platinum resistant setting make this STRO-002 data not competitive?
If Mirvetuximab is approved based on SORAYA and MIRASOL, how should STRO-002 be developed. What is the best setting and comparator
Added By: user1ae2bf5fExamination of the STRO-002 dose expansion spider plot to assess the drug's activity and potential
Added By: user1ae2bf5fFolate Receptor Alpha as a target in Ovarian cancer. Overall thoughts on the target based on historical data from multiple agents and various failures. Is it still a good target for OC?
Added By: user1ae2bf5fAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
